Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations

Simone Garcia,^{1,2} Carolina O. Ramos,¹ Juliana F. V. Senra,¹ Fabio Vilas-Boas,³
Maurício M. Rodrigues,⁴ Antonio C. Campos-de-Carvalho,²
Ricardo Ribeiro-dos-Santos,¹ and Milena B. P. Soares^{1*}

Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz,¹ and Hospital Santa Izabel,³ Salvador, Bahia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro,² and Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo,⁴ Brazil

Received 20 July 2004/Returned for modification 26 September 2004/Accepted 20 December 2004

Chagas' disease, caused by *Trypanosoma cruzi* infection, is one of the main causes of death due to heart failure in Latin American countries. Benznidazole, the chemotherapeutic agent most often used for the treatment of chagasic patients, is highly toxic and has limited efficacy, especially in the chronic phase of the disease. In the present study we used a mouse model of chronic Chagas' disease to investigate the effects of benznidazole treatment during the chronic phase on disease progression. The hearts of benznidazole-treated mice had decreased parasitism and myocarditis compared to the hearts of untreated chagasic mice. Both groups of *Trypanosoma cruzi*-infected mice had significant alterations in their electrocardiograms compared to those of the healthy mice. However, untreated mice had significantly higher cardiac conduction disturbances than benznidazole-treated mice, including intraventricular conduction disturbances, atrioventricular blocks, and extrasystoles. The levels of antibodies against *T. cruzi* antigens (epimastigote extract, P₂β, and trans-sialidase) as well as antibodies against peptides of the second extracellular loops of β₁-adrenergic and M₂-muscarinic cardiac receptors were also lower in the sera from benznidazole-treated mice than in the sera from untreated mice. These results demonstrate that treatment with benznidazole in the chronic phase of infection prevents the development of severe chronic cardiomyopathy, despite the lack of complete parasite eradication. In addition, our data highlight the role of parasite persistence in the development of chronic Chagas' disease and reinforce the importance of *T. cruzi* elimination in order to decrease or prevent the development of severe chagasic cardiomyopathy.

Chagas' disease, caused by the protozoan *Trypanosoma cruzi*, is a serious health problem in Latin America, where it affects 16 million to 18 million people (43). In the acute phase of the disease in humans, clinical signs are usually mild, despite high levels of parasitemia in blood, which is characteristic of this phase of infection and which declines with the onset of immunity (18). After this phase, individuals recover to an apparently healthy status, but a mild focal myocarditis may persist and may last for years without signs of cumulative damage in the indeterminate phase of the disease (3). Many years after the primary infection, about 30% of these individuals develop the symptomatic chronic phase of Chagas' disease. This phase is characterized by the presence of myocarditis and/or pathological disturbances in the peripheral nervous and gastrointestinal systems (15, 37).

The most common chronic form of the disease is chagasic cardiomyopathy, a fatal form for which no effective treatments are available. It is characterized by focal or disseminated inflammatory infiltrates, myocytolysis, and myonecrosis and pro-

gressive deposition of fibrotic tissue (11, 29). The intensity of the myocarditis varies considerably from light cardiac symptoms to intense chronic cardiomyopathy, leading to heart failure and death (31). Patients with chronic chagasic cardiomyopathy may have diverse arrhythmias that cause heart malfunction. The most frequent alterations recorded are ventricular premature beats, complete right bundle branch block, left anterior fascicular block, and atrioventricular block (27).

The mechanisms responsible for the cardiomyopathy are not clearly understood, but the presence of chronic myocardial injury in the absence of parasitemia suggests the participation of autoimmune processes (21, 26, 35). Many hypotheses have been proposed to explain the cardiomyopathy of Chagas' disease, and these proposed causes of cardiomyopathy may act alone or in combination. They include the breakdown of the tolerance to self-antigens induced by polyclonal activation of the immune system by the parasite (33) or by *T. cruzi*-specific immune responses cross-reactive to self-antigens through a mechanism of molecular mimicry (13, 24), *T. cruzi*-specific immune responses acting in the residual parasites during the chronic phase of infection (34), and microvascular abnormalities (30). Several *T. cruzi* antigens have epitopes similar to those of mammalian cardiac antigens, such as cardiac myosin and the second loop of the human β₁-adrenergic receptor (16, 38). Antibodies from chronic chagasic patients induce β₁-ad-

* Corresponding author. Present address: Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão, 121, Brotas, Salvador, BA CEP 40295-001, Brazil. Phone: (55) (71) 356-8787, ext. 260. Fax: (55) (71) 356-8784, ext. 292. E-mail: milena@cpqgm.fiocruz.br.

renergic and M_2 -muscarinic effects on the myocardium, resulting in alterations of electrocardiographic (ECG) findings correlated to electrical abnormalities, as described in the literature (12, 14). However, there is also evidence that parasite persistence or reinfection influences the severity of the disease (8, 41). This may be due to the direct participation of anti-*T. cruzi* immune responses and/or by its influence on autoimmune responses (35).

The main drug available for the treatment for Chagas' disease is benznidazole, whose action eliminates *T. cruzi* parasites. This compound, however, has limited efficacy and a degree of high toxicity. In humans, benznidazole treatment is effective at parasite eradication mainly in the acute phase of infection but not in the prevalent chronic stage of the disease (10). Several studies have investigated the efficacy of benznidazole treatment during chronic infection in mice. In those studies (1, 2, 9, 32, 39), the investigators focused on the analysis of parasite eradication and confirmed in the mouse model that benznidazole treatment during the chronic phase does not completely eliminate the parasite. The effects of benznidazole treatment for experimental chronic chagasic myocarditis are controversial. Segura et al. (32) did not observe a significant decrease in myocarditis in mice treated with benznidazole during the chronic phase of infection, whereas in the work by Andrade et al. (1), when parasitological cure was achieved, benznidazole-treated mice had a decreased incidence of myocarditis.

Given the lack of therapeutic options for Chagas' disease, the potential benefits of benznidazole treatment in the chronic phase of the disease should be carefully examined. In the present study we used a murine model of chronic chagasic cardiomyopathy caused by a myotropic *T. cruzi* strain to re-evaluate the beneficial effects of benznidazole treatment during the chronic phase of Chagas' disease. The goal of the benznidazole treatment was to cause a decrease in the residual parasite load present during the chronic phase of infection and analyze its influence on the development of heart alterations characteristic of this disease. The decrease in parasitism resulting from the benznidazole treatment were correlated to histopathological and ECG parameters, as well as to the levels of antibodies specific for *T. cruzi* antigens and β_1 -adrenergic and M_2 -muscarinic receptors, in order to determine if the treatment results in decreased heart pathology even in absence of a parasitological cure.

MATERIALS AND METHODS

Animals, infection, and chemotherapy. Two-month-old male BALB/c mice, raised and maintained in the animal facilities at the Gonçalo Moniz Research Center, Fundação Oswaldo Cruz, were used in the experiments and were provided with rodent diet and water ad libitum. Mice were infected by intraperitoneal injection of 100 trypomastigote forms of the Colombian strain of *T. cruzi* (17). Trypomastigotes were obtained by in vitro infection of LCC-MK2 cells. Parasitemia was evaluated at different times after infection by counting the number of trypomastigotes in peripheral blood aliquots placed between a glass slide and a coverslip (6). Forty-five days after infection, a group of 10 mice was treated by the oral route with 100 mg of benznidazole (Rochagan; Roche) per kg of body weight daily for 1 week, followed by weekly administrations for an additional 8 months. All animals were killed while they were under anesthesia and were handled according to the guidelines of the National Institutes of Health for the ethical use of laboratory animals.

ECG records. ECGs were performed with a Bio Amp device PowerLab System (PowerLab 2/20; ADInstruments, Castle Hill, Australia), which recorded bipolar lead I. All animals were anesthetized by intraperitoneal injection of xylazine at 10

mg/kg of body weight and ketamine at 100 mg/kg of body weight. ECG recordings were obtained after the induction of general anesthesia. All data were acquired on a computer for further analysis by using Chart 5 for Windows software (Power Lab; ADInstruments). Wave durations (in milliseconds) were calculated automatically by the software after placement of the cursors. Measurements are average values determined from 14 consecutive ECG records. Records were filtered (1 to 100 Hz) through a band-pass filter to minimize environmental signal disturbances. The sampling rate was 1 kHz. The ECG analysis included the following measurements: heart rate, PR interval, P-wave duration, QT interval, QTc, atrioventricular block, intraventricular block, and other arrhythmias. The software used a derivative-based QRS detection algorithm to calculate the heart rate by detecting the peaks of the R waves automatically. As the T waves are normally not separated from the QRS complex in rodent ECGs (5), we measured the QT interval instead of the QRS complex duration. The QT interval was measured from the beginning of the QRS to the end of the T wave. The definition of the end of the T wave was the point where the signal returned to the isoelectric line (42). The QTc was calculated as the ratio of the QT interval to the square root of the RR interval.

Histopathological analysis. The hearts of the benznidazole-treated mice and untreated controls were removed and fixed in buffered 10% formalin. Sections of paraffin-embedded tissue were stained by the standard hematoxylin-eosin and Sirius red staining methods for evaluation of inflammation and fibrosis, respectively, by optical microscopy. Images were digitalized with a color digital video camera (CoolSnap, Montreal, Quebec, Canada) adapted to a BX41 microscope (Olympus, Tokyo, Japan). The images were analyzed with the Image Pro program (version 5.0; Media Cybernetics, San Diego, Calif.) to integrate the number of inflammatory cells counted by the area. The cells in 10 fields per heart from each mouse in each group were counted.

Immunofluorescence for parasite detection. Five-micrometer-thick frozen heart sections were prepared in a cryostat in poly-L-lysine-coated slides and were fixed with cold acetone. Sections were incubated with phosphate-buffered saline (PBS)–5% bovine serum albumin for 30 min, followed by overnight incubation with anti-*T. cruzi* rat serum (1:400). After the sections were washed with PBS, they were incubated for 1 h with fluorescein isothiocyanate-conjugated rabbit anti-rat immunoglobulin G (1:100; Sigma) adsorbed with normal mouse serum. The sections were washed three times, counterstained with Evans blue, and mounted with Vectashield (Vector). Images were digitalized with a color digital video camera (DP-70) adapted to an Olympus AX-70 microscope with a motorized stage xyz (Media Cybernetics) and in a FV-500 confocal system with an IX 81 inverted microscope (Olympus). The images were analyzed by use of the Image Pro program (version 5.0; Media Cybernetics) so that the parasite foci could be counted and integrated by the area.

Antigen preparations. Epimastigotes of the Colombian strain of *T. cruzi* were obtained from axenic cultures grown in liver infusion tryptose medium. The parasites were washed three times in PBS at 4°C, resuspended in distilled water, and submitted to five cycles of freezing and thawing. The extract was made isotonic by addition of PBS concentrated 10-fold and was centrifuged at 30,000 $\times g$ for 30 min. The supernatant was aliquoted and stored at –70°C. Recombinant P_{2B} was kindly donated by Mariano Levin. Recombinant *trans*-sialidase (TS) was produced and purified from *Escherichia coli* cells transformed with plasmid pTS-cat7, as described previously (28). Peptides of the second extracellular loops of β_1 -adrenergic (residues 197 to 222) and M_2 -muscarinic (residues 164 to 185) cardiac receptors were synthesized in an automatic peptide synthesizer by the 9-fluorenylmethoxy carbonyl technique by using solid-phase automatic synthesis. Their purities were checked by high-performance liquid chromatography after cleavage and desalting on a P2 column.

Antibody detection. Sera from untreated, benznidazole-treated, and uninfected mice were tested for the presence of antibodies against *T. cruzi* antigen, TS, P_{2B} , and the M_2 -muscarinic and β_1 -adrenergic cardiac receptors by enzyme-linked immunosorbent assay. Microtiter plates (Maxisorb; Nunc) were coated overnight at 4°C with *T. cruzi* antigen (3 μ g/ml), P_{2B} (1.5 μ g/ml), TS (1 μ g/ml), and the M_2 -muscarinic and β_1 -adrenergic cardiac receptor peptides (500 ng/ml) in 50 μ l of carbonate-bicarbonate buffer (pH 9.6). The plates were washed three times in washing buffer (0.05% Tween 20 in PBS) and blocked with PBS–5% nonfat milk for 2 h at room temperature. The sera were diluted 1:100 (for P_{2B}), 1:800 (for *T. cruzi* antigen), 1:1,200 (for TS), and 1:25 (for the M_2 -muscarinic and β_1 -adrenergic cardiac receptor peptides) in PBS–5% nonfat milk and incubated for 2 h at room temperature. After the plates were washed, 50 μ l of peroxidase-conjugated anti-mouse polyvalent immunoglobulins (Sigma) diluted 1:1,000 was dispensed into each well and the plate was incubated for 30 min at room temperature. The plates were washed eight times in washing buffer, and the reaction was developed with the 3,3',5,5'-tetramethylbenzidine substrate (Sigma)

FIG. 1. Parasitemia during the acute phase of infection with the Colombian strain of *T. cruzi* in BALB/c mice. BALB/c mice were infected with 100 trypomastigotes of the Colombian strain of *T. cruzi*. Parasitemia was determined at different times after infection. Values represent the medians for five mice. The arrow indicates the beginning of benznidazole administration.

and read at 450 nm in a Spectramax 190 microplate reader (Molecular Devices, Sunnyvale, Calif.).

Statistical analyses. Histological and serological data were analyzed by Student's *t* test, one-way analysis of variance, and the Newman-Keuls multiple-comparison test, as indicated in the text, with Prism Software (version 3.0; GraphPad Software, San Diego, Calif.). Statistical analyses of the cardiac parameters were performed with SPSS software (version 9.0; SPSS Inc., Chicago, Ill.). The values for all continuous variables are presented as means $\pm$ standard errors. To test if the variables were normally distributed, we performed the Kolmogorov-Smirnov test. Nonparametric tests (the Kruskal-Wallis and/or the Mann-Whitney test) were used because the variables were not normally distributed by two-tailed hypothesis testing. Differences were considered significant if *P* was equal to or less than 0.05.

RESULTS

Decreased parasitism and myocarditis in benznidazole-treated mice. In order to investigate the effects of benznidazole treatment in the chronic phase of *T. cruzi* infection, BALB/c mice were treated with benznidazole for 8 months after the acute phase of infection (Fig. 1). The hearts of mice in both the untreated and the benznidazole-treated groups had detectable parasite foci 10 months after infection (Fig. 2A and B). How-

FIG. 2. Parasitism and histopathological analyses of heart sections of *T. cruzi*-infected mice. Heart sections of untreated (A and C) or benznidazole-treated (B and D) *T. cruzi*-infected mice were analyzed for the presence of parasite foci by confocal microscopy (A and B; magnification, $\times 60$) or inflammation by staining with hematoxylin-eosin (C and D; magnification, $\times 40$).

FIG. 3. Decreased parasitism and inflammation in the hearts of benznidazole-treated mice determined by quantification of parasite foci (A), inflammatory cells (B), and fibrosis (C) in heart sections of *T. cruzi*-infected BALB/c mice untreated (I) or treated with benznidazole (I + B). Values represent the means $\pm$ standard deviations for 5 mice per group (A) and 8 to 10 mice per group (B and C). *, $P < 0.05$ compared to the results for the untreated infected group by Student's *t* test.

ever, the number of parasite foci was threefold higher ($P < 0.01$) in the hearts of untreated mice than in those of benznidazole-treated mice (Fig. 3A). Histopathological analysis of heart sections also demonstrated a twofold reduction ($P < 0.02$) in the numbers of inflammatory cells in benznidazole-treated mice (Fig. 3B). No significant differences were observed ($P > 0.05$) when the fibrotic areas of the hearts from untreated and benznidazole-treated mice were compared (Fig. 3C).

Benznidazole treatment prevents the development of ECG alterations in chronic Chagas' disease. To investigate whether benznidazole treatment in the chronic phase of infection ameliorates the cardiac function, ECG analysis was performed 10 months after infection. Both groups of *T. cruzi*-infected mice had significant alterations ($P < 0.05$) in various ECG parameters compared to those for the healthy mice, such as an increased intrinsicoid deflection and an increased QT interval (Table 1 and Fig. 4). Alterations in these parameters indicate a delay in the conduction of the electric impulse and an increase in the duration of the ventricular action potential. More importantly, the ECGs of all untreated *T. cruzi*-infected animals showed severe cardiac conduction disturbances, such as intraventricular conduction disturbances, atrioventricular blocks, and extrasystoles (Table 1 and Fig. 4A). In contrast,

only 20% of the benznidazole-treated mice had cardiac conduction disturbances (intermittent intraventricular conduction disturbances), while the remaining animals did not have any conduction disturbances (Fig. 4B). Intermittent conduction disturbances are clinically relevant but are much less severe than the permanent intraventricular conduction disturbances observed in the untreated infected animals. The heart rates of the healthy mice were lower than those of the untreated and benznidazole-treated mice, but the differences between the healthy and chagasic mice were not statistically significant (Table 1).

Decreased anti-*T. cruzi* antibody levels after benznidazole treatment. The levels of antibodies against different *T. cruzi* antigens were investigated. Sera from benznidazole-treated mice had decreased levels of antibodies against *T. cruzi* extract ($P < 0.001$) compared to those in the sera of untreated *T. cruzi*-infected mice (Fig. 5A). The levels of antibodies against TS, an immunodominant *T. cruzi* antigen, were also significantly lower ($P < 0.01$) in benznidazole-treated mice (Fig. 5B). Benznidazole-treated mice also had lower levels of antibodies against $P_2\beta$ ($P < 0.01$), a member of the acidic ribosomal protein family from the protozoan parasite *T. cruzi* with structural similarities with cardiac receptors (Fig. 5C). The levels of antibodies against peptides from the second extracellular loops of the β_1 -adrenergic and the M_2 -muscarinic receptors were also decreased in benznidazole-treated mice compared to the levels in untreated *T. cruzi*-infected mice (Fig. 5D and E).

DISCUSSION

Parasite persistence occurs in most individuals infected with *T. cruzi*. This can be demonstrated by diagnostic techniques and can be illustrated by the recrudesence of the infection in many patients with heart failure due to Chagas' disease who

TABLE 1. Electrocardiographic parameters measured in the experimental groups^a

Experimental group (no. of mice)	Heart rate (no. of beats/ min)	PR interval (ms)	P-wave duration (ms)	PR segment (ms)	Intrinsicoid deflection (ms)	QT interval (ms)	QT	Cardiac conduction disturbances (no. of mice)
Infected (8)	270.3 ± 30.3	39 ± 2.6	18.5 ± 2.4	21.9 ± 1.4	16.1 ± 2.9	41 ± 2.5	2.9 ± 0.2	IVCD (5), AVB (2), ES (1)
Infected and treated with benznidazole (10)	256.7 ± 15.7	35.5 ± 2.1 ^b	21.6 ± 0.9	13.2 ± 1.4 ^b	15.8 ± 1.7	43.5 ± 2.8	2.6 ± 0.2	IT-IVCD (2)
Healthy (18)	215.3 ± 18.5	36.5 ± 1.2	19.7 ± 0.7	16.9 ± 0.8 ^c	9 ± 0.7 ^c	32.2 ± 1.4 ^c	1.9 ± 0.9 ^c	IT-IVCD (1), ASI (1)

^a Values represent the means ± standard errors of the means for individual mice. IVCD, intraventricular conduction disturbance; AVB, atrioventricular block; ES, extrasystole; IT-IVCD, intermittent intraventricular conduction disturbance; ASI, acute subendocardial ischemia.

^b *P* < 0.05 compared to the results for untreated infected mice.

^c *P* < 0.05 compared to the results for the *T. cruzi*-infected groups.

FIG. 4. ECG recordings from BALB/c mice. ECGs of untreated (A) and benznidazole-treated (B) *T. cruzi*-infected mice were recorded 10 months after infection. (C) ECG for a healthy BALB/c mouse. ▼, P wave; Δ, QRS complex; *, second-degree atrioventricular block.

FIG. 5. Decreased levels of antibodies in sera from benznidazole-treated mice. Sera of untreated (I) or benznidazole-treated (I + B) *T. cruzi*-infected and health (N) BALB/c mice were tested by enzyme-linked immunosorbent assay in order to determine the levels of antibodies against *T. cruzi* antigen (A), TS (B), P₂β (C), the second extracellular loop of the human M₂-muscarinic cardiac receptor (D), and the second extracellular loop of the human β₁-adrenergic cardiac receptor (E). The data represent the means ± standard deviations for 5 to 10 mice for each group. *, *P* < 0.05 compared to the results for the untreated infected group by one-way analysis of variance followed by Newman-Keuls multiple-comparison test. O.D., optical density.

undergo cardiac transplantation. When these patients are immunosuppressed, myocarditis usually develops in the transplanted heart and *T. cruzi* parasites are detected in the blood and tissues (22, 36). Benznidazole is the main drug used for the

treatment of *T. cruzi* infection. However, although it is effective when it is administered during the acute phase of the infection, treatment with benznidazole is not believed to be able to eliminate the parasite during the chronic phase of infection (10). It

has been proposed that latent forms of the *T. cruzi* parasite present in tissues during the chronic phase of infection are not eliminated by the chemotherapy (7).

In this report we demonstrated with a mouse model of infection that although parasite eradication could not be achieved with benznidazole treatment in the chronic phase, a decrease in the parasite load could be observed. More importantly, we demonstrated for the first time that benznidazole treatment caused a decrease in cardiac dysfunction (ECG alterations) and myocarditis, indicating that parasite persistence plays an important role in the pathogenesis of chronic chagasic cardiomyopathy. The observations of Bustamante and coworkers (8) that reexposure to parasites through repeated infections aggravates heart dysfunction corroborates this idea.

The beneficial effects of benznidazole treatment were achieved by using a prolonged administration of a low dose in mice infected with the Colombian strain of *T. cruzi*, a chemotherapy-resistant strain (1, 40). Thus, it is likely that benznidazole treatment is even more effective against chronic infections caused by benznidazole-sensitive *T. cruzi* strains. In addition, due to the high degree of toxicity of benznidazole, a low-dose treatment similar to the one used in this work may be more tolerable for humans.

Our results demonstrate that the sera of benznidazole-treated mice had lower levels of antibodies specific to *T. cruzi* antigens (trypomastigote extract, TS, and P₂β) than the sera of the untreated group. It is possible that the higher antibody levels participate in the increased severity of heart dysfunction in untreated mice, as antibodies against *T. cruzi* antigens may exert effects on cross-reactive epitopes on cardiac receptors and modulate the function of the heart. In fact, it was observed that sera from untreated mice had higher titers of antibodies that recognized peptides from the second extracellular loop of β₁-adrenergic and M₂-muscarinic cardiac receptors. Sera from chronic chagasic patients with severe cardiac arrhythmias induced conduction disturbances, such as bradycardia and atrioventricular conduction blockade, in isolated rabbit hearts perfused by the Langendorff technique. The effects of these sera and immunoglobulin G fractions were abolished by atropine, suggesting an involvement of the M₂-muscarinic receptor (14). By using an experimental model, it was demonstrated that antibodies of chronic chagasic patients bind to the M₂-muscarinic cardiac receptor in a noncompetitive manner and are able to activate the receptor in an agonist-like form inducing L-type Ca²⁺ current inhibition (20). These results could well be correlated with clinical reports, since inhibition of this current provokes atrioventricular blockade.

TS is an enzyme abundant on the *T. cruzi* parasite surface and an immunodominant antigen recognized by sera from patients with Chagas' disease. In the present study we also observed that benznidazole treatment decreased the levels of antibodies against TS. This finding is reinforced by a recent study (25) that demonstrated that benznidazole treatment of Chagas' disease patients induces a decrease in the reactivity of serum against recombinant TS that correlates with parasite elimination.

The higher incidence of severe cardiac abnormalities in untreated mice was striking. All animals from this group had disturbances in heart electrogenesis. The alterations, intraventricular conduction disturbances, atrioventricular blocks, and extrasystoles, are characteristic of chronic chagasic cardiomyopathy. As

mentioned above, the lower antibody levels in benznidazole-treated mice may account for the better performance in cardiac function in these animals. These data are in accordance with those from previous reports which demonstrated that mice immunized with recombinant *T. cruzi* ribosomal P₂β protein, which reproduced the typical anti-P profile characteristic of chronic infections, had ECG alterations without cardiac inflammatory lesions (4). Thus, in untreated mice, the higher levels of antibodies and heart inflammation could explain the finding of cardiac conduction disturbances in the animals in this group, whereas in benznidazole-treated mice these aggressive factors were decreased, resulting in better heart performance.

Chronic chagasic cardiomyopathy is a dilated cardiomyopathy accompanied by acute and chronic inflammation, fibrosis, and vasculitis. The mechanism by which this persistent inflammatory reaction occurs is not clearly known and occurs in only about 25% of *T. cruzi*-infected individuals. Several reports have recently demonstrated a role of autoimmune responses in experimental models of chronic chagasic myocarditis (19, 23, 26). However, although the intensities of tissue parasitism and inflammation do not have a direct correlation, parasite persistence is probably required for disease development and maintenance (35). In this study, we observed a correlation between decreased inflammation and parasitism in the myocardiums of benznidazole-treated mice, which reinforces the importance of residual parasitism in the development of chronic chagasic myocarditis. As shown in a previous study (35), the profile of the host's immune response during *T. cruzi* infection is also important in the development of the disease.

In conclusion, our results demonstrate the importance of benznidazole treatment in chronic chagasic patients in order to decrease or retard the development of chagasic cardiopathy, even though complete parasite eradication is not achieved. In addition, it reinforces the need for the discovery of new anti-*T. cruzi* drugs with higher degrees of efficacy against the chronic infection and fewer collateral effects. This will allow the more efficient elimination of the parasite from *T. cruzi*-infected individuals and proper treatment of those patients who cannot be treated with benznidazole due to its high degree of toxicity.

ACKNOWLEDGMENTS

This work was supported by grants from the Brazilian Ministry of Science and Technology (Brazilian National Research Council-CNPq and Millenium Institute of Tissue Bioengineering), an NIH grant (grant HL073732-01), FAPESB, and FAPESP.

REFERENCES

- Andrade, S. G., J. B. Magalhaes, and A. L. Pontes. 1989. Therapy of the chronic phase of the experimental infection by *Trypanosoma cruzi* with benznidazole and nifurtimox. *Rev. Soc. Bras. Med. Trop.* 22:113-118.
- Andrade, S. G., S. Stocker-Guerret, A. S. Pimentel, and J. A. Grimaud. 1991. Reversibility of cardiac fibrosis in mice chronically infected with *Trypanosoma cruzi*, under specific chemotherapy. *Mem. Inst. Oswaldo Cruz* 86:187-200.
- Andrade, Z. A. 1999. Immunopathology of Chagas disease. *Mem. Inst. Oswaldo Cruz* 94(Suppl. 1):71-80.
- Bergami, P. L., P. C. Meckert, D. Kaplan, G. Levitus, F. Elias, F. Quintana, M. V. Regenmortel, R. Laguens, and M. J. Levin. 1997. Immunization with recombinant *Trypanosoma cruzi* ribosomal P₂β protein induces changes in the electrocardiogram of immunized mice. *FEMS Immunol. Med. Microbiol.* 18:75-85.
- Bestetti, R. B., and J. S. Oliveira. 1990. The surface electrocardiogram: a simple and reliable method for detecting overt and latent heart disease in rats. *Braz. J. Med. Biol. Res.* 23:1213-1222.
- Brener, Z. 1973. Biology of *Trypanosoma cruzi*. *Annu. Rev. Microbiol.* 27:347-382.

7. Brener, Z., Z. A. Andrade, and M. Barral-Neto. 2000. *Trypanosoma cruzi* e doença de Chagas, 2nd ed. Guanabara Koogan, Rio de Janeiro, Brazil.
8. Bustamante, J. M., H. W. Rivarola, A. R. Fernandez, J. E. Enders, R. Fretes, J. A. Palma, and P. A. Paglini-Oliva. 2002. *Trypanosoma cruzi* reinfections in mice determine the severity of cardiac damage. *Int. J. Parasitol.* **32**:889–896.
9. Camandoroba, E. L. P., E. A. G. Reis, M. S. Gonçalves, M. G. Reis, and S. G. Andrade. 2003. *Trypanosoma cruzi*: susceptibility to chemotherapy with benznidazole of clones isolated from highly resistant Colombian strain. *Rev. Soc. Bras. Med. Trop.* **36**:201–209.
10. Cançado, J. R. 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. *Rev. Inst. Med. Trop.* **44**:29–37.
11. Chiale, P. A., and M. B. Rosenbaum. 1989. Clinical and pharmacological characterization and treatment of potentially malignant arrhythmias of chronic chagasic cardiomyopathy, p. 601–620. *In* E. M. Vaughan Williams and T. J. Campbell (ed.), *Handbook of experimental pharmacology*. Springer-Verlag, Berlin, Germany.
12. Chiale, P. A., I. Ferrari, E. Mahler, M. A. Vallazza, M. V. Elizari, M. R. Rosenbaum, and M. J. Levin. 2001. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. *Circulation* **103**:1765–1771.
13. Davies, J. M. 1997. Molecular mimicry: can epitope mimicry induce autoimmune disease? *Immunol. Cell Biol.* **75**:113–126.
14. de Oliveira, S. F., R. C. Pedrosa, J. H. M. Nascimento, A. C. Campos de Carvalho, and M. O. Masuda. 1997. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. *Circulation* **96**:2031–2037.
15. Dias, J. C. P., and J. R. Coura. 1997. Epidemiologia, p. 36–66. *In* J. C. P. Dias and J. R. Coura (ed.), *Clínica e terapêutica da doença de Chagas: uma abordagem prática para o clínico geral*. Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
16. Ferrari, I., M. J. Levin, G. Wallukat, R. Elies, D. Lebesgue, P. A. Chiale, M. Elizari, M. B. Rosenbaum, and J. Hoebeke. 1995. Molecular mimicry between the immunodominant ribosomal protein P0 of *Trypanosoma cruzi* and a functional epitope on the human beta 1-adrenergic receptor. *J. Exp. Med.* **182**:59–65.
17. Frederici, E. E., W. N. Abelman, and F. A. Neva. 1964. Chronic and progressive myocarditis in C3H mice infected with *Trypanosoma cruzi*. *Am. J. Trop. Med. Hyg.* **13**:272–280.
18. Giordanengo, L., N. Guinazu, C. Stempin, R. Fretes, F. Cérban, and S. Gea. 2002. Cruzipain, a major *Trypanosoma cruzi* antigen, conditions the host immune response in favor parasite. *Eur. J. Immunol.* **32**:1003–1011.
19. Girones, N., and M. Fresno. 2003. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? *Trends Parasitol.* **19**:19–22.
20. Hernández, C. C. Q., L. C. Barcellos, L. E. D. Giménez, R. A. B. Cabarcas, S. Garcia, R. C. Pedrosa, J. H. M. Nascimento, E. Kurtenbach, M. O. Masuda, and A. C. Campos de Carvalho. 2003. Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca^{2+} currents. *Cardiovasc. Res.* **58**:55–65.
21. Kierszenbaum, F. 1999. Chagas' disease and the autoimmunity hypothesis. *Clin. Microbiol. Rev.* **12**:210–223.
22. Kirchhof, L. V. 1993. American trypanosomiasis (Chagas' disease)—a tropical disease now in the United States. *N. Engl. J. Med.* **329**:639–644.
23. Leon, J. S., and D. M. Engman. 2003. The significance of autoimmunity in the pathogenesis of Chagas heart disease. *Front. Biosci.* **8**:e315–e322.
24. Levin, M. J., E. Mesri, R. Benarous, G. Levitus, A. Schijman, P. Levy-Yeyati, P. A. Chiale, A. M. Ruiz, A. Kahn, M. B. Rosenbaum, H. N. Torres, and E. L. Segura. 1989. Identification of major *Trypanosoma cruzi* antigenic determinants in chronic Chagas' heart disease. *Am. J. Trop. Med. Hyg.* **41**:530–538.
25. Pereira-Chiocola, V. L., A. A. Fragata-Filho, A. M. Levy, M. M. Rodrigues, and S. Schenkman. 2003. Enzyme-linked immunoassay using recombinant *trans*-sialidase of *Trypanosoma cruzi* can be employed for monitoring of patients with Chagas' disease after drug treatment. *Clin. Diagn. Lab. Immunol.* **10**:826–830.
26. Pontes-de-Carvalho, L., C. C. Santana, M. B. Soares, G. G. Oliveira, E. Cunha-Neto, and R. Ribeiro-dos-Santos. 2002. Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. *J. Autoimmun.* **18**:131–138.
27. Rassi, A., and A. Q. Luquetti. 1992. Therapy of Chagas disease, p. 237–247. *In* S. Wendel, Z. Brener, M. E. Camargo and A. Rassi (ed.), *Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine*. ISBT, Sao Paulo, Brazil.
28. Ribeiro, M., V. L. Pereira-Chiocola, D. Eichinger, M. M. Rodrigues, and S. Schenkman. 1997. Temperature differences for *trans*-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of *Trypanosoma cruzi trans*-sialidase. *Glycobiology* **7**:1237–1246.
29. Rosenbaum, M. B. 1964. Chagasic myocardiopathy. *Prog. Cardiovasc. Dis.* **7**:199–225.
30. Rossi, M. A., and R. B. Bestetti. 1995. The challenge of chagasic cardiomyopathy. The pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications. *Cardiology* **86**:1–7.
31. Schmunis, G. A. 1987. Autoimmunity in Chagas' disease. *Mem. Inst. Oswaldo Cruz* **82**(Suppl. 1):287–310.
32. Segura, M. A., E. M. de Raspi, and M. A. Basombrio. 1994. Reversibility of muscle and heart lesion in chronic, *Trypanosoma cruzi* infected mice after late trypanocidal treatment. *Mem. Inst. Oswaldo Cruz* **89**:213–216.
33. Smith, H. R., and A. D. Steinberg. 1983. Autoimmunity—a perspective. *Annu. Rev. Immunol.* **1**:175–210.
34. Soares, M. B., L. Pontes-De-Carvalho, and R. Ribeiro-dos-Santos. 2001. The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet. *An. Acad. Bras. Cienc.* **73**:547–559.
35. Soares, M. B. P., K. N. Silva-Mota, R. S. Lima, M. C. Bellintani, L. Pontes-de-Carvalho, and R. Ribeiro-dos-Santos. 2001. Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. *Am. J. Pathol.* **159**:703–709.
36. Stolf, N. A. G., L. Higushi, E. Bocchi, G. Bellotti, J. O. C. Auler, D. Uip, V. A. Neto, F. Pileggi, and A. D. Janete. 1987. Heart transplantation in patients with Chagas' disease cardiomyopathy. *J. Heart Transplant.* **6**:307–312.
37. Tanowitz, H. B., L. V. Kirchhoff, D. Simon, A. S. Morris, L. M. Weis, and M. Wittner. 1992. Chagas' disease. *Clin. Microbiol. Rev.* **5**:400–419.
38. Tibbets, R. S., T. S. McCormick, E. C. Rowland, S. D. Miller, and D. M. Engman. 1994. Cardiac antigen-specific autoantibody production is associated with cardiomyopathy in *Trypanosoma cruzi*-infected mice. *Immunology* **152**:1493–1499.
39. Toledo, M. J. O., M. T. Bahia, V. M. Veloso, C. M. Carneiro, G. L. L. Machado-Coelho, C. F. Alves, H. R. Martins, R. E. Cruz, W. L. Tafuri, and M. Lana. 2004. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different *Trypanosoma cruzi* clonal genotypes. *J. Antimicrob. Chemother.* **53**:1045–1053.
40. Veloso, V. M., C. M. Carneiro, M. J. Toledo, M. Lana, E. Chiari, W. L. Tafuri, and M. T. Bahia. 2001. Variation in susceptibility to benznidazole in isolates derived from *Trypanosoma cruzi* parental strains. *Mem. Inst. Oswaldo Cruz* **96**:1005–1011.
41. Viotti, R., C. Vigliano, H. Armenti, and E. Segura. 1994. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. *Am. Heart J.* **127**:151–162.
42. Wang, L., S. Wirp, and H. Duff. 2000. Age-dependent response of the electrocardiogram to K^{+} channel blockers in mice. *Am. J. Physiol.* **278**:C73–C78.
43. World Health Organization. 1995. Chagas' disease: important advances in elimination of transmission in four countries in Latin America. W. H. O. Press Office Feature no. 183. World Health Organization, Geneva, Switzerland.